Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient

BACKGROUND: Trastuzumab plus chemotherapy remains the standard first-line treatment strategy for HER2-positive gastric cancer (GC). Trastuzumab resistance, on the other hand, remains a significant issue. There are a few effective anti-HER2 agents for patients who develop resistance to trastuzumab. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Junyi, Li, Lei, Qin, Jun, Yan, Zhengqing, Chen, Shiqing, Jin, Tao, Xu, Junming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829539/
https://www.ncbi.nlm.nih.gov/pubmed/35155188
http://dx.doi.org/10.3389/fonc.2021.780577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829539/
https://www.ncbi.nlm.nih.gov/pubmed/35155188
http://dx.doi.org/10.3389/fonc.2021.780577

Ejemplares similares